Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole.
about
Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazoleAntibiotic treatment for Helicobacter pylori: Is the end coming?CYP2C19 polymorphism influences Helicobacter pylori eradicationClinical relevance of genetic polymorphisms in the human CYP2C subfamilySummary of information on human CYP enzymes: human P450 metabolism data.Evaluation of the pharmacokinetic interaction between lesogaberan (AZD3355) and esomeprazole in healthy subjects.Levofloxacin-amoxicillin/clavulanate-rabeprazole versus a standard seven-day triple therapy for eradication of Helicobacter pylori infectionAntiplatelet drug interactions with proton pump inhibitorsInfluences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypesIncidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysisPharmacogenetics of the proton pump inhibitors: a systematic review.Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials.Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy.Influence of inflammatory cytokine polymorphisms on eradication rates of Helicobacter pylori.Systematic review: Rabeprazole-based therapies in Helicobacter pylori eradication.A phase 1 randomized study evaluating the effect of omeprazole on the pharmacokinetics of a novel 5-hydroxytryptamine receptor 4 agonist, revexepride (SSP-002358), in healthy adultsThe value of branded proton pump inhibitors: formulary considerations.Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?Effect of bacterial and host factors on Helicobacter pylori eradication therapyEffects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypesDifferent effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.CYP2C19 polymorphism and proton pump inhibitors.Review article: efficacy and safety of rabeprazole in treating gastroesophageal reflux disease.Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors--overview and clinical implications.Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.Review article: treatment for gastro-oesophageal reflux disease--lifestyle advice and medication.Efficacy of esomeprazole in treating acid-related diseases in Japanese populationsImprovement in symptoms after H2-receptor antagonist-based therapy for eradication of H pylori infection.Use of Proton-Pump Inhibitors Predicts Heart Failure and Death in Patients with Coronary Artery Disease.Rabeprazole experience in Korea; focus on CYP2C19 polymorphism.CYP2C19 genotype and the PPIs--focus on rabeprazole.Clinical application of pharmacogenetics in gastrointestinal diseases.A review of rabeprazole in the treatment of acid-related diseasesEffect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians.Non-Carriers of Reduced-Function CYP2C19 Alleles are Most Susceptible to Impairment of the Anti-Platelet Effect of Clopidogrel by Proton-Pump Inhibitors: A Pilot Study.Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics.Population pharmacokinetics of omeprazole in a random Iranian population.Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy.
P2860
Q26741015-DA6A7274-1788-4F0E-92E2-881304211D62Q26777623-F50EC898-696C-4C9A-9B41-936480669995Q27005916-7FF04270-58D5-4366-A8AE-7D485E5CFE77Q28362533-0F2C79A9-CAC9-47C3-A286-F705BB67BA30Q32103802-40BC0090-84B3-4CA2-9F80-33497667BEDDQ33448993-C8DEE545-EF39-4BCC-BB3C-14ED0F090C20Q33790850-4E9D68A9-29EA-438F-B3D0-3571A1A02FB2Q33948811-8A50D7A9-33B1-4479-AE06-7BB808697ADEQ34174915-9B1EB436-AC12-44E2-A9EF-3B9462299084Q34486149-CAE316B4-F18E-4A7B-AB9D-63D2E31A1ACAQ34532600-449C2365-9065-459C-B2CD-A6E8F3BDAB1EQ34706721-CBDB0731-67E7-4DAD-9997-2434E4B4228FQ35056670-D275FE9E-60CB-46AA-BC7C-C4878CE4175CQ35082607-BCB1CEDC-6366-404F-8C0D-CD91CFE895B3Q35086840-CB178ED4-42B6-4243-9944-B4FE1378D5CAQ35161564-AFDF4204-6231-44DC-A583-950440CD69A6Q35209935-954FD2E8-0DDE-4E82-AE47-ED2EDEBFEDEBQ35373698-A0C4B7B8-2BF5-4095-ACF5-EDEFFA8A6883Q35738262-08462444-EEDF-4055-983F-F995F5E73D2CQ35826832-FC4A90FA-9661-4485-AF45-94BC617FF31BQ35827117-9835E246-906C-45A9-BEC6-5266188D95EAQ35827444-411F5539-52AA-484D-81E3-D1AB524F6B23Q35827487-FE75F3F7-AF16-4402-8B92-1D24DC3C8727Q35831792-96C58DFE-1D72-4518-87F3-16F56E11B7ECQ35868527-DEDD8A7A-A063-4088-AC51-9C0955ED3219Q35923949-B422BB80-DA02-4562-962F-479D076E94E2Q35923954-8C33E0DA-34AB-44D2-A154-E778BC7B67BCQ35970047-D10F2393-B699-43A1-B6ED-C688FECF2F2DQ35987201-CE8085FD-721A-47D0-93A5-08D35BFA32F8Q36177968-86EA191D-8BA6-454A-8EAB-5EBBBE121B2EQ36254177-6FE03901-7EAA-47A1-900F-24CF06F76DD1Q36344149-F01B67CC-6141-4617-A437-0FE4A205B775Q36344158-801C4B82-C59D-4044-AD33-09709B0B585CQ36613862-D34B7BBF-493E-4668-8437-11B34F8BFD6AQ36661321-2AC40A52-3C4B-4136-8EB6-82749B6DBE91Q36729180-2970FC41-621F-4B94-B5D7-F6364D33289FQ36754362-9D96ECC0-F3FB-4251-8BB2-8137BEBA5AFDQ36979297-D3B06CDA-8873-42AE-B8E4-566B16DB54E6Q37128495-1E49FDA3-5E74-4B6E-8F94-915D84A5C4ECQ37156268-5C408ABE-D722-47EC-8496-BF4683390ED4
P2860
Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole.
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Review article: cytochrome P45 ...... tors--emphasis on rabeprazole.
@ast
Review article: cytochrome P45 ...... tors--emphasis on rabeprazole.
@en
type
label
Review article: cytochrome P45 ...... tors--emphasis on rabeprazole.
@ast
Review article: cytochrome P45 ...... tors--emphasis on rabeprazole.
@en
prefLabel
Review article: cytochrome P45 ...... tors--emphasis on rabeprazole.
@ast
Review article: cytochrome P45 ...... tors--emphasis on rabeprazole.
@en
P2860
P1476
Review article: cytochrome P45 ...... tors--emphasis on rabeprazole.
@en
P2093
P2860
P356
10.1046/J.1365-2036.1999.00022.X
P407
P478
13 Suppl 3
P577
1999-08-01T00:00:00Z